Skip to main content
main-content

01.08.2011 | Viewpoint | Ausgabe 4/2011

Breast Cancer Research 4/2011

Estrogen receptor degradation: a CUE for endocrine resistance?

Zeitschrift:
Breast Cancer Research > Ausgabe 4/2011
Autor:
Elizabeth A Musgrove
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Abstract

Despite the undoubted success of adjuvant endocrine therapies that target the estrogen receptor pathway, not all women with estrogen receptor-positive breast cancer respond to these therapies, and many who initially respond will subsequently relapse. Deregulation of various aspects of estrogen receptor signaling has been highlighted as a mechanism of resistance and as a basis for alternative therapeutic approaches. However, a recent publication refocuses attention on the estrogen receptor itself by showing that the ubiquitin-binding CUE domain-containing protein 2 is a regulator of estrogen receptor protein degradation and a marker of endocrine resistance in breast cancer.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2011

Breast Cancer Research 4/2011 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise